DelveInsight’s “Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Hospital-acquired and Ventilator-associated Bacterial Pneumonia, historical and forecasted epidemiology as well as the HABP/VABP market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market with DelveInsight’s In-Depth Report @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Size

Key Takeaways from the Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Report

• As per DelveInsight’s estimates, the incident cases of bacterial pneumonia were highest in the United States among the 7MM in 2024.
• As per the analysis, HABP is more common as compared to VABP in the United States.
• According to the findings, S.aureus, P.aeruginosa, Klebsiella, E.coli, Acinetobacter species and Enterobacter species are pathogens, which are most likely to cause HABP or VABP.
• The leading HABP/VABP Companies such as Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aridis Pharmaceuticals, Aerucin, Aridis Pharmaceuticals, Motif Bio and others.
• Promising HABP/VABP Therapies such as IMI/REL FDC, Linezolid, OMN6, Combination of Imipenem/Cilastatin and XNW4107, doripenem, Imipenem, Relebactam, Cilastatin and others.

Stay ahead in the Hospital-acquired and Ventilator-associated Bacterial Pneumonia Therapeutics Market with DelveInsight’s Strategic Report @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Outlook

Hospital-acquired and Ventilator-associated Bacterial Pneumonia Epidemiology

• Total Hospital-acquired and Ventilator-associated Bacterial Pneumonia Incident Cases
• Hospital-acquired and Ventilator-associated Bacterial Pneumonia Etiology-specific Cases
• Hospital-acquired and Ventilator-associated Bacterial Pneumonia Treated Cases

Download the report to understand which factors are driving Hospital-acquired and Ventilator-associated Bacterial Pneumonia Epidemiology trends @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Prevalence

Hospital-acquired and Ventilator-associated Bacterial Pneumonia Marketed Drugs

• XACDURO: Innoviva

XACDURO, a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, was approved in May 2023 for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The FDA designated it as a Qualified Infectious Disease Product. In July 2022, Innoviva acquired Entasis Therapeutics, the developer of sulbactam-durlobactam.

• FETROJA (cefiderocol): Shionogi

FETROJA (cefiderocol) is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore. In addition to entering cells by passive diffusion through porin channels, FETROJA binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient for bacteria. These mechanisms allow FETROJA to achieve high concentrations in the periplasmic space where it can bind to penicillin-binding proteins and inhibit cell wall synthesis in the bacterial cells. FETROJA has also demonstrated in vitro activity against certain bacteria that contain very problematic resistant enzymes such as ESBLs, AmpC, serine- and metallo-carbapenemases. The drug was approved in September 2020 for the treatment of patients 18 years of age or older with HABP/VABP caused by the following susceptible Gram-negative microorganisms: Acinetobacter baumannii complex, Escherichia coli, Enterobacter cloacae complex, Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia marcescens.

Hospital-acquired and Ventilator-associated Bacterial Pneumonia Emerging Drugs

• AR-301: Aridis Pharmaceuticals

AR-301 (tosatoxumab) is a fully human monoclonal IgG1 antibody that targets the alpha-toxin produced by S. aureus, a significant virulence factor in both MRSA and MSSA infections. By neutralizing alpha-toxin, AR-301 prevents the destruction of host cells, thereby preserving immune function. Importantly, its mechanism of action is not impacted by the antibiotic resistance of the S. aureus strain, making it effective against both MRSA and MSSA infections.

• BV100: Bioversys

BV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing an active uptake of rifabutin into the Gram-negative bacterial species, Acinetobacter baumannii. The candidate allows to target RNA-polymerase in Gram-negative bacteria for the first time with a human-suitable dose.

To learn more about Hospital-acquired and Ventilator-associated Bacterial Pneumonia treatment guidelines, visit @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Treatment Market Landscape

Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Outlook

Key players, such as Aridis Pharmaceuticals, Bioversys, Omnix Medical, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of HABP/ VABP. The United States accounts for the largest market size of Hospital-acquired and Ventilator-associated Bacterial Pneumonia, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Scope of the Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Hospital-acquired and Ventilator-associated Bacterial Pneumonia Companies- Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aridis Pharmaceuticals, Aerucin, Aridis Pharmaceuticals, Motif Bio and others.
• HABP/VABP Therapies- IMI/REL FDC, Linezolid, OMN6, Combination of Imipenem/Cilastatin and XNW4107, doripenem, Imipenem, Relebactam, Cilastatin and others.
• Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Dynamics: Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Drivers and Barriers
• Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Hospital-acquired and Ventilator-associated Bacterial Pneumonia Drugs in development @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Clinical Trials Assessment

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary of Hospital-acquired and Ventilator-associated Bacterial Pneumonia

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Overview at a Glance

7 Disease Background and Overview

8 Diagnostic Algorithm for Hospital-acquired and Ventilator-associated Bacterial Pneumonia

9 Epidemiology and Patient Population: 7MM

10 Treatment

11 Patient Journey

12 Unmet Needs

13 SWOT Analysis

14 Marketed Drugs

15 Emerging Drugs

16 Hospital-acquired and Ventilator-associated Bacterial Pneumonia: 7MM Analysis

17 KOL Views

18 SWOT Analysis

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market